Mandate

Vinge has advised Carrier in connection with the sale of its remaining stake in Beijer Ref

December 08, 2020 Capital Markets and Public M&A

Carrier Global Corporation (“Carrier”) is a leading global provider of heating, ventilating and air conditioning (HVAC), refrigeration, fire, security and building automation technologies, and is listed on the New York Stock Exchange. Beijer Ref AB (publ) (“Beijer Ref”) provides commercial and industrial refrigeration as well as heating and air conditioning products and is listed on Nasdaq Stockholm.

Carrier announced on 7 December 2020 that the company had signed a definitive agreement to sell its remaining interest in Beijer Ref to a fund managed by EQT. Under the terms of the agreement with EQT, Carrier’s remaining interest will be sold for a total value of approximately USD 1.1 billion (SEK 9.2 billion). The transaction is expected to close by the end of December 2020, subject to the receipt of a required regulatory approval. The sale follows an accelerated equity offering that occurred in September 2020 through which Carrier sold 9.25 million B shares of Beijer Ref and received proceeds of approximately USD 300 million.  

Vinge’s team consisted of Charlotte Levin, Linnéa Sellström and Anders Sundin Lundberg.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024